TY - JOUR T1 - Prediction of vascular-platelet hemostasis disorders in patients with chronic obstructive pulmonary disease (COPD) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.3284 VL - 56 IS - suppl 64 SP - 3284 AU - Yuliia Huba AU - Viktoriia Yakovlieva AU - Lyudmyla Konopkina Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/3284.abstract N2 - There is evidence that decrease respiratory function and systemic inflammation in patient with COPD may also contribute to the violation of vascular-platelet hemostasis. But we know little about the methods for early prediction of these disorders.Aim: to evaluate the value of the platelet adhesion activity index (PAA) in predicting the development of disorders of vascular-platelet hemostasis in patients with COPD.Material and Methods: we have examined 85 patients (age – 64,7±5,4 yrs, male–73 (85,9%)) with COPD I-IV stage. Were studied the clinical status, spirometry and PAA (%) of COPD patients. Assessments of vascular-platelet hemostasis were performed by optical aggregometry with adenosine diphosphate (ADP) and collagen as aggregation inducers. A ROC-analysis was used to assess the prognostic potential of the PAA indicator. Control group (gr) included 25 practically healthy persons.Results: patients with COPD had level of PAA above (43,0 [32,3–48,6] % ) compared to the control gr (27,0 [24,0–32,0] %) (p<0,05). Hyperaggregate disorders were identified in 42 (51,42 %) patients. The results of the ROC-analysis showed that the PAA has high diagnostic accuracy (Area Under Curve = 0.769), high levels of sensitivity (92.4 %) and specificity (90.2 %) for the prediction of hyperaggressive disorders in ADP and collagen-induced aggregation. The cut-off point was > 41.0 %.Conclusion: According to the ROC-analysis, the PAA indicator was determined as the optimal prognostic indicator for the prediction of vascular-platelet hemostasis disorders in patients with COPD. The level of PAA above 41.0 % in COPD patients indicates hyperagregation.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3284.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -